| Original language | English |
|---|---|
| Pages (from-to) | 8-9 |
| Number of pages | 2 |
| Journal | The Lancet Oncology |
| Volume | 23 |
| Issue number | 1 |
| DOIs |
|
| Publication status | Published - Jan 2022 |
| Externally published | Yes |
Bibliographical note
Funding Information:LELH reports research funding from AstraZeneca, Boehringer Ingelheim, and Roche Genentech; negotiation for funding from Beigene and Takeda; advisory board work for Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Merck Sharp & Dohme, Pfizer, Roche Genentech, and Takeda; speaker work for Merck Sharp & Dohme; travel and conference reimbursement from Roche Genentech; mentorship programme with key opinion leaders, funded by AstraZeneca; fees for educational webinars from Benecke, high5oncology, Medtalks, and VJOncology; interview sessions funded by Bayer and Roche Genentech; was or is the local principal investigator of clinical trials for AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, GlaxoSmithKline, Janssen Pharmaceuticals, Mirati, Merck Sharp & Dohme, Merck, Novartis, Roche Genentech, and Takeda; is on the guideline committee for European Society for Medical Oncology and Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose (Dutch Society of Physicians for Pulmonary Diseases and Tuberculosis); and unpaid secretary activities for the Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose (Dutch Society of Physicians for Pulmonary Diseases and Tuberculosis) studies foundation. DKMDR reports grants from AstraZeneca, BMS, Olink, Philips Health, and Seattle Genetics.
